Aerie Pharma (AERI) Reports In-Line Q1 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Aerie Pharma (AERI) Reports In-Line Q1 EPS

Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

May 5, 2022 4:01 PM EDT

First Quarter Glaucoma Franchise Net Revenues of $29.8 Million, up 30% over First Quarter 2021

Management Reaffirms 2022 Glaucoma Franchise Guidance of $130 Million to $140 Million

First Phase 3 Registrational Trial for AR-15512 On-Track for Enrollment Second Quarter of 2022

DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today reports financial results for the first quarter ended March 31, 2022 and reaffirms the business and pipeline objectives and financial guidance... More